Followers | 2 |
Posts | 118 |
Boards Moderated | 0 |
Alias Born | 11/19/2019 |
Monday, March 30, 2020 4:37:34 PM
https://patch.com/new-york/new-york-city/nyc-doctor-who-separated-conjoined-twins-dies-coronavirus
NYC Doctor Who Separated Conjoined Twins Dies Of Coronavirus
Dr. James T. Goodrich, who captivated the world when he separated two infant twins with intertwined brains, died from COVID-19 Monday.
By Kathleen Culliton, Patch Staff
Mar 30, 2020 1:47 pm ET | Updated Mar 30, 2020 4:13 pm ET
NEW YORK CITY — A New York City neurosurgeon who made medical history when he separated two infant twins with intertwined brains died from novel coronavirus, Montefiore Hospital announced.
Dr. James T. Goodrich, pediatric neurosurgery chief at Albert Einstein College of Medicine, died from COVID-19 complications Monday morning, hospital officials confirmed.
"Our beloved colleague, mentor, teacher, brother-in-arms passed away early this morning," the hospital wrote in a tweet.
"As a last act of service to others, he will forever remind us that Covid-19 is not a faceless disease. He will always be in our hearts."
The hospital did not immediately respond to Patch's request for more information.
Goodrich earned worldwide acclaim in 2017 when he famously separated Anias and Jadon McDonald, cranially conjoined 13-month-old boys, during a 27-hour long surgery.
Years later, their mom Nicole McDonald cried in a video interview as she described Goodrich and what his expertise and dedication meant for her family.
"I was told their was no chance that I would have a child," McDonald said, noting both the boys were attending school. "It's what you dream of, I guess."
Goodrich used his skill at separating cranially conjoined twins — which relied on virtual planning and 3D printing technologies — to help families from across the globe.
Goodrich separated Filipino twins Clarence and Carl Aguirre in 2004 and, as CBS News reported, the boys celebrated their 10th birthdays in Scarsdale in 2014.
"When they were born, the doctors at home told me, 'You have to choose which one is to live,'" their mother, Arlene Aguirre, said. "The doctors here did not ask me to choose."
More recently, Goodrich helped separate twin girls Ysabelle and Ysadora Freitas, from Ceará, Brazil in 2019.
"They were born again," their mother Débora Freitas said at the time. "First by me, second by the doctors. I am so happy, I'm going to jump and my heart is going to explode."
Goodrich is a graduate of the University of California, Irvine, Columbia University and completed his residency at Presbyterian Hospital in New York City and the New York Neurological Institute.
Recent AMRN News
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • Oct 15, 2024 8:21 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
CBD Life Sciences, Inc. Announces Strategic MOU with U.S. Armed Forces for Groundbreaking Mushroom Supplement • CBDL • Oct 15, 2024 8:00 AM
HealthLynked Files Non-Provisional Patent for AI-Powered Healthcare Assistant, ARi • HLYK • Oct 15, 2024 8:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM